Lantern Pharma Inc. · NASDAQ:LTRN
Lantern Pharma — Rare Disease Innovation & Partnership Summit in Philadelphia (March 2023)
27 slides from Lantern Pharma's conference presentation, Mar 20, 2023
Slide 1: How AI is Transforming Drug Development
Lantern Pharma Inc. How AI is Transforming Drug Development March 20th, 2023 Leveraging A.I., machine learning & genomics to transform the cost, pace, and timeline of oncology drug discovery and development NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Current Oncology Drug Development is Costly, Risky, and Inefficient
Current Oncology Drug Development is Costly, Risky, and Inefficient A perfect problem area for artificial intelligence & machine learning …are being met by data-driven, and Challenges in drug development… A.I.-enabled approaches & technology 3.4% $2.8B Avg. success rate of R&D investment to bring a
Slide 4: Using AI, Lantern is Transforming Drug Discovery Timelines and Cost
Using AI, Lantern is Transforming Drug Discovery Timelines and Cost Lantern has launched 9 programs in two years, and is anticipating launching Multiple Phase 1 trials in 2023 Lantern’s Drug Development Model Large Scale/Multi-omics Proprietary AI Accelerated timeline Oncology Data platform RADR® an
Slide 5: Drug Development Advances are Needed To Improve Outcomes for Rare Cancer Patients
Drug Development Advances are Needed To Improve Outcomes for Rare Cancer Patients Rare Cancer Facts and Statistics: Rare cancers are 25% of all The number of rare cancers is Rare cancer 5-year survival There is a lack of of rare cancer cases and and are the growing, there are over 500 rates are wors
Slide 6: RADR is Lantern's AI and ML Platform that Powers Oncology Drug Discovery and Development
RADR® is Lantern’s AI and ML Platform that Powers Oncology Drug Discovery and Development Response Algorithm for Drug Positioning & Rescue A proprietary integrated data analytics, experimental biology, oncology-focused, machine- learning-based platform focused on drug development 80%+ Leverages cutt
Slide 7: Lantern Pharma is a Top 10 End-to-End AI Drug Discovery Company
Lantern Pharma is a Top 10 End-to-End AI Drug Discovery Company According to Deep Pharma Intelligence (May 04, 2022) NASDAQ: LTRN 6
Slide 8: RADR has Multi-Faceted Modules that are Facilitating Oncology Drug Discovery and Development
RADR® has 4 Multi-Faceted Modules that are Facilitating Oncology Drug Discovery and Development of Lantern and its Collaborators Use RADR® to find potential Identify and prioritize Mechanism of Action (MoA) of type/subtype of cancer for the Compound / Drug your compound with use of RADR® RADR® can d
Slide 9: RADR's Library of Over 200+ Advanced Algorithms Powers its Multi-Faceted Modules
RADR®’s Library of Over 200+ Advanced Algorithms Powers its Multi-Faceted Modules Example RADR® Algorithms Ensemble Deep Learning Bayesian Based Tree Based Rule Based Clustering Others Examples Regression • Predicting drug sensitivity values, e.g. IC50 Supervised Learning • Predicting blood brain ba
Slide 10: RADR's Framework to Develop Actionable AI Insights Using Billions of Datapoints
RADR®‘s Framework to Develop Actionable AI Insights Using Billions of Datapoints Input Data RADRⓇ Derived Insights Actionable Insights FDA Orphan Identified PTGR1 as a biomarker that Identified glioblastoma as target Drug Designation predicts LP-184 response indication using PTGR1 Validation of RADR
Slide 11: Lantern's Collaborators are Leveraging RADR to Accelerate the Development of their Drug Candidates
Lantern’s Collaborators are Leveraging RADR® to Accelerate the Development of their Drug Candidates Actuate Therapeutics, Inc. is a private clinical stage TTC Oncology is an emerging biotechnology company founded biopharmaceutical company focused on the in 2015. TTC Oncology’s mission is to develop
Slide 12: RADR Facilitates the Rapid and Cost-effective Development of Drug Assets
RADR® Facilitates the Rapid and Cost-effective Development of Drug Assets Framework of Lantern’s RADR® collaboration with Actuate Therapeutics Input Data RADRⓇ Derived Insights Actionable Insights Drug Developing a response biomarker panel for use in Phase II clinical trials Patient A neural network
Slide 13: RADR's Capabilities Enhanced with Increased Focus on the Development of Antibody Drug Conjugates
RADR®’s Capabilities Enhanced with Increased Focus on the Development of Antibody Drug Conjugates What are Antibody Drug Conjugates (ADCs)? Antibody Drug Conjugates (ADCs) are highly specific cancer-targeted antibodies linked to potent anti-tumor small molecules and designed for the treatment of can
Slide 14: RADR Is a Top Performing A.I. Platform for Predicting a Drug's Blood Brain Barrier Permeability
RADR® Is a Top Performing A.I. Platform for Predicting a Drug’s Blood Brain Barrier Permeability Using the drug SMILE structure information, RADR® can create more than 4500 features that represent the atomic properties of a drug, including fingerprints and descriptors Drug SMILEs Drug Structure Drug
Slide 15: RADR's Blood Brain Barrier Predictions Validated in the Wet Lab
RADR®’s Blood Brain Barrier Predictions Validated in the Wet Lab RADR®, in silico, Predicted Blood Brain Wet Lab, in vitro, validated Blood Brain Barrier Barrier Permeability of LP-184 Permeability of LP-184 A. B. 1.0 BBB Permeable BBB Permeable Probability of BBB Permeability 2.0×10-4 0.8 BBB Perme
Slide 16: Lantern's Diverse & Unique AI Driven Pipeline of Drug Programs
Lantern’s Diverse & Unique AI Driven Pipeline of Drug Programs Lantern has 12 disclosed drug programs including an ADC program and the Phase 2 Harmonic™ trial Program Indication Discovery Optimization Preclinical Pre IND Phase I Phase II LP-300 Non-Small Cell Lung Cancer (NSCLC) LP-100 Homologous Re
Slide 17: LP-184 has a Unique Mechanism of Action Leveraging Synthetic Lethality
LP-184 has a Unique Mechanism of Action Leveraging Synthetic Lethality LP-184’s MoA was predicted by RADR® and validated with in-vitro/in-vivo studies A. RADR® Insight (in-silico) B. In-vitro Gene Editing Studies (CRISPR) PTGR1 activates LP-184 into its highly potent and cytotoxic form In-vitro expe
Slide 18: Cancer Models with Common DNA Damage Response Deficiencies are Highly Sensitive to LP-184 Treatment
Cancer Models with Common DNA Damage Response Deficiencies are Highly Sensitive to LP-184 Treatment PDX model Cancer type IC50 (nM) DDR Mutations LP-184 Completely Inhibits Tumor Growth in Triple Negative ctg1194 NSCLC 31 ATM Breast Cancer (TNBC) PDX Mouse Models ctg2440 Prostate 31 PMS2 ctg1522 Pan
Slide 19: Lantern and NCI A.I.-Driven Collaboration Identify ATRT Sensitivity to LP-184
Lantern and NCI A.I.-Driven Collaboration Identify ATRT Sensitivity to LP- 184 – Published in Frontiers in Drug Discovery ● Systematic comparison of drug activity demonstrated key differences among alkylating agents that inform positioning ● Integrated multi-omic data bioinformatic analysis provides
Slide 20: Atypical Teratoid Rhabdoid Tumors (ATRT) are ultra-rare and highly malignant pediatric CNS tumors
Atypical Teratoid Rhabdoid Tumors (ATRT) are ultra-rare and highly malignant pediatric central nervous system (CNS) tumors There is NO STANDARD OF CARE for ATRT patients. New lines of therapy that are SAFE and Effective are critically needed to improve the lives and outcomes of these patients 19
Slide 21: Gene Enrichment Analysis Predicts Cancers Deficient in DNA Damage Repair to be Uniquely Sensitive to LP-184
Gene Enrichment Analysis Predicts Cancers Deficient in DNA Damage Repair/Chromatin Remodeling to be Uniquely Sensitive to LP-184 LP-184 Response is Strongly Correlated With Gene Sets Gene’s Associated with Chromatin Remodeling Involved with DNA Repair and Chromatin Remodeling are Strongly Negatively
Slide 22: Sensitivity to LP-184 is Significantly Negatively Correlated With Driver Mutations of ATRT
Sensitivity to LP-184 is Significantly Negatively Correlated With Driver Mutations of ATRT A. LP-184 Sensitivity is Negatively Correlated B. LP-184 Sensitivity is Negatively Correlated with with SMARCB1 Gene Expression SMARCA4 Gene Expression 21
Slide 23: RADR Predicts ATRT Sensitive in Patients with Limited Patient Gene Expression Data
RADR® Predicts ATRT Sensitive in Patients with Limited Patient Gene Expression Data M.L. model prediction of LP-184 sensitivity in ATRT M.L. prediction of LP-184 sensitivity in ATRT patients patients with either no SMARC mutation, a SMARCB1, with different genetic SMARCB1 genetic subtypes or SMARCA4
Slide 24: ATRT Cancer Cells are Exceptionally Sensitive to LP-184 – Validating RADR Predictions
Atypical Teratoid Rhabdoid Tumor Cancer Cells are Exceptionally Sensitive to LP-184 – Validating RADR® Predictions CDX ATRT mouse model treated with LP-184 LP-184 treatment leads to near-complete tumor regression in ATRT mouse xenograft models Time Course of ATRT CDX Mouse Tumors Terminal ATRT Mouse
Slide 25: Lantern's A.I.-Driven Collaborative Model for the Rapid and Cost-effective Development of Drug Candidates
Lantern’s A.I.-Driven Collaborative Model for the Rapid and Cost-effective Development of Drug Candidates Framework of Lantern’s RADR® collaboration with Actuate Therapeutics Input Data RADRⓇ Derived Insights Actionable Insights Drug Developing a response biomarker panel for use in Phase II clinical
Slide 26: RADR and A.I. Technologies Have the Potential to Make Rapid and Meaningful Advancements for Rare Cancer Therapies
RADR® and A.I. Technologies Have the Potential to Make Rapid and Meaningful Advancements for Therapies for Rare Cancer Patients How A.I. and M.L.. Can Help Drug Development for Rare Cancers: Build M.L. models of drug response from existing preclinical/clinical data Generate M.L.-driven biomarker sig
Slide 27: IR Contact
IR Contact: IR@lanternpharma.com 1-972-277-1136 Nasdaq: LTRN www.lanternpharma.com @LanternPharma Sign up for the Spark Newsletter www.lanternpharma.com/media/newsletter#subscriptionSec CONNECT WITH US 26
Lantern Pharma — Rare Disease Innovation & Partnership Summit in Philadelphia (March 2023) on 6ix